Status:
ACTIVE_NOT_RECRUITING
Research for the Molecular Imaging of the PD-L1 Targeting Tracer
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Solid Tumor
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To use the molecular probe PET radionuclide (Ga-68 or F-18) WL12 peptide to detect the expression of PD-L1 in the primary and metastatic lesions in patients with solid tumor; to detect the expression ...
Detailed Description
In many clinical trials, Anti-PD-1/PD-L1 mAbs have achieved great success than expected in a variety of refractory and recurrent tumor patients. The latest research shows that it is not all cancer pat...
Eligibility Criteria
Inclusion
- 1\. Aged \>18 years old; ECoG 0 or 1;
- 2\. Patients with solid tumors;
- 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
- 4\. life expectancy \>=12 weeks.
Exclusion
- 1\. Significant hepatic or renal dysfunction;
- 2\. Is pregnant or ready to pregnant;
- 3\. Cannot keep their states for half an hour;
- 4\. Refusal to join the clinical study;
- 5\. Suffering from claustrophobia or other mental diseases;
- 6\. Any other situation that researchers think it is not suitable to participate in the experiment.
Key Trial Info
Start Date :
August 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04304066
Start Date
August 6 2019
End Date
December 1 2024
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shunlian Zhou
Beijing, China